BofA lowered the firm’s price target on Guardant Health to $35 from $38 and keeps a Buy rating on the shares. Following Q4 results and guidance, the firm updates forecasts, raising FY24 sales but trimming outyear estimates largely for more conservative minimal residual disease, or MRD, test volume assumptions, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GH:
- Guardant Health Announces Board Member Samir Kaul’s Resignation
- Guardant Health price target lowered to $54 from $64 at Craig-Hallum
- Guardant Health’s preliminary Q4 results well ahead of consensus, says Canaccord
- Guardant Health sees FY23 revenue $562M-$563M, consensus $555.18M
- Guardant Health reports preliminary Q4 revenue $153M-$154M, consensus $146.34M
Questions or Comments about the article? Write to editor@tipranks.com